Contineum Therapeutics, Inc. Class A Common StockCTNMNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank50
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Latest
-6.93%
↓ 115% vs avg
Percentile
P50
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
44.77%
Historical baseline
PeriodValue
Q4 2025-6.93%
Q3 202522.12%
Q2 2025-8.67%
Q1 2025-41.27%
Q4 2024-65.38%
Q3 202426.20%
Q2 2024-3.01%
Q1 202424.19%
Q4 2023-99.07%
Q3 2023-113.22%
Q2 2023875.63%
Q1 2023-28.62%
Q4 20220.00%